Liminatus Pharma announces a $30 million investment agreement with CTG to advance immunotherapy research and development.
Quiver AI Summary
Liminatus Pharma, Inc. announced a Memorandum of Understanding (MOU) with New Zealand-based Capital Trust Group Limited for a $30 million equity financing to support its immunotherapy research. The investment is contingent upon due diligence and the negotiation of definitive agreements, with the intent for CTG to purchase newly issued shares in compliance with Nasdaq and U.S. securities laws. Both companies aim to finalize agreements in November 2025 and plan to explore further strategic cooperation, including potential digital bond financing programs. Liminatus CEO Chris Kim expressed optimism about the partnership, highlighting the financial strengthening it brings to the company.
Potential Positives
- Liminatus Pharma has secured a USD 30,000,000 equity financing through a Memorandum of Understanding with Capital Trust Group, which will support its research and development efforts in immunotherapy.
- This financing has the potential to significantly strengthen Liminatus's financial foundation, enabling further advancements in their next-generation CD47-blockade therapies.
- The partnership with Capital Trust Group may lead to additional strategic cooperation, including future digital bond financing programs, highlighting the company’s proactive approach to exploring diverse funding opportunities.
- The announcement of the MOU indicates a positive outlook for Liminatus Pharma and its commitment to establishing long-term partnerships within the investment community.
Potential Negatives
- The reliance on an MOU with CTG for a significant equity financing of USD 30,000,000 indicates that Liminatus Pharma may be facing financial constraints and is seeking external funding to support its R&D efforts.
- The press release's emphasis on forward-looking statements underscores uncertainties regarding the completion of definitive agreements and potential regulatory hurdles, creating an impression of instability in their financial strategy.
- The mention of potential future digital bond financing programs may suggest that Liminatus is exploring alternative financing options due to challenges in raising capital through traditional means.
FAQ
What is the Memorandum of Understanding between Liminatus Pharma and CTG?
Liminatus Pharma and CTG have signed an MOU for a USD 30 million equity financing to support immunotherapy research.
How will the equity financing benefit Liminatus Pharma?
The equity financing aims to strengthen Liminatus's financial foundation for developing next-generation immuno-oncology therapies.
What future collaboration is planned after the MOU?
Both companies plan to discuss further strategic cooperation, including potential digital bond financing programs starting mid-November.
When are the definitive agreements expected to be finalized?
The definitive agreements between Liminatus Pharma and CTG are expected to be finalized in November 2025.
What is Liminatus Pharma's focus in the immuno-oncology space?
Liminatus Pharma specializes in developing next-generation CD47-blockade therapies design to improve treatment for solid tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus’s research and development of advanced immunotherapy assets.
Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. securities laws. The subscription funds are expected to be remitted following the submission and effectiveness of a registration statement relating to the resale of the shares. Both parties aim to finalize and execute the definitive agreements in November 2025.
In addition to the equity investment, beginning in mid-November this year and subject to definitive agreements being signed, Liminatus and CTG plan to commence discussions for further strategic cooperation, including potential future digital bond financing programs.
“We believe that this MOU marks the beginning of a long-term partnership with CTG,” said Chris Kim, Chief Executive Officer of Liminatus Pharma. “The equity financing would strengthen our financial foundation.”
About Liminatus Pharma, Inc. (NASDAQ: LIMN)
Liminatus Pharma is a clinical-stage immuno-oncology company pioneering next-generation therapeutics, including its proprietary CD47-blockade antibody IBA101, designed to overcome the limitations of first-generation immune therapies in solid tumors.
About Capital Trust Group Limited (CTG)
Capital Trust Group is a New Zealand-based investment management and digital finance firm managing large-scale institutional and blockchain-enabled financing programs across healthcare, energy, and infrastructure sectors. CTG has the privilege of having General Chavalit Yongchaiyudh, the 22nd Prime Minister of Thailand, as one of its shareholders and an honorable advisor.
Contacts
Liminatus Pharma, Inc.:
Chris Kim, CEO —
[email protected]
, (213) 273-5453
Capital Trust Group:
Wasupit Wises, Director —
[email protected]
, +66 61 7722142
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected equity investment, timing of definitive agreements, potential future digital bond programs, and anticipated financial and strategic benefits. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those described herein. Factors that may cause such differences include, among others, the ability to finalize and execute definitive agreements, regulatory and market conditions, and the availability of financing. Liminatus undertakes no obligation to update or revise any forward-looking statements, except as required by law.
